Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?
Appetite For Weight Loss Drug Remains Insatiable
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.
The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.
The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.